Navigation Links
Semafore to Present at BIO CEO & Investor Conference
Date:2/8/2008

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marshall or Ed Jacobs David Schull or Timothy Engel

(480) 278-8200 (212) 845-4271


'/>"/>
SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):